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McMinn, Julie E., Charles W. Wilkinson, Peter J.
Havel, Stephen C. Woods, and Michael W. Schwartz,.
Effect of intracerebroventricular a-MSH on food intake,
adiposity, c-Fos induction, and neuropeptide expres-
sion. Am J Physiol Regulatory Integrative Comp Physiol
279: R695–R703, 2000.—a-Melanocyte-stimulating hor-
mone (a-MSH) is a hypothalamic neuropeptide proposed to
play a key role in energy homeostasis. To investigate the
behavioral, metabolic, and hypothalamic responses to
chronic central a-MSH administration, a-MSH was in-
fused continuously into the third cerebral ventricle of rats
for 6 days. Chronic a-MSH infusion reduced cumulative
food intake by 10.7% (P , 0.05 vs. saline) and body weight
by 4.3% (P , 0.01 vs. saline), which in turn lowered plasma
insulin levels by 29.3% (P , 0.05 vs. saline). However,
a-MSH did not cause adipose-specific wasting nor did it
alter hypothalamic neuropeptide mRNA levels. Central
a-MSH infusion acutely activated neurons in forebrain
areas such as the hypothalamic paraventricular nucleus,
as measured by a 254% increase in c-Fos-like immunore-
activity (P , 0.01 vs. saline), as well as satiety pathways in
the hindbrain. Our findings suggest that, although an
increase of central melanocortin receptor signaling acutely
reduces food intake and body weight, its anorectic potency
wanes during chronic infusion and causes only a modest
decrease of body weight.
melanocortin; hypothalamus; body weight
a-MELANOCYTE-STIMULATING HORMONE (a-MSH) and its an-
alogs acutely suppress food intake after intracerebro-
ventricular administration in rats and mice (6, 11, 14,
23, 29, 31, 40, 41). Several observations suggest a
physiological role for this anorectic response to a-MSH.
For example, conditions associated with an increased
drive to consume food, such as fasting (2, 5) and genetic
leptin deficiency (26, 36), are accompanied by reduced
expression of the gene encoding proopiomelanocortin
(POMC; the precursor molecule for a-MSH) in the
hypothalamic arcuate nucleus (Arc). Conversely,
POMC mRNA is upregulated in the overfed state (15)
and by acute injections of leptin (26, 36). In addition,
rodents and humans with mutations of the gene encod-
ing POMC, or POMC processing enzymes, are obese
and hyperphagic (20, 30).
After its release from axon terminals in hypotha-
lamic areas such as the paraventricular nucleus
(PVN), a-MSH binds to and activates neuronal mela-
nocortin-4 (MC-4) receptors. Intracerebroventricularly
administered MC-4 receptor antagonists acutely stim-
ulate food intake (11, 33), and MC-4 receptor-deficient
mice (19) and humans (42) have an obese phenotype,
suggesting that this receptor subtype plays a major
role in the anorectic action of a-MSH. The agouti
mouse is also obese, presumably due to ectopic produc-
tion the melanocortin receptor antagonist agouti in the
brain (11). Agouti-related peptide (AgRP) is a naturally
occurring endogenous antagonist to the MC-4 receptor
that is synthesized in a subset of Arc neurons adjacent
to POMC cells. Centrally administered AgRP blocks
the catabolic action of a-MSH and increases food in-
take when given intracerebroventricularly, suggesting
that melanocortin signaling is essential to constrain
food intake. AgRP is colocalized with neuropeptide Y
(NPY) in Arc neurons, and, similar to NPY, AgRP is
upregulated in response to fasting (16, 27), leptin de-
ficiency (27, 43), and streptozotocin-induced diabetes
(18), suggesting that AgRP also plays a physiological
role in body weight regulation. We therefore hypothe-
sized that chronic intracerebroventricular infusion of
a-MSH would promote a sustained state of negative
energy balance, leading to a reduction in body weight.
Candidate targets of first-order neurons releasing
a-MSH include second-order neurons that express the
catabolic peptide corticotropin-releasing hormone
(CRH), contained in the parvocellular region of the
PVN, as well as second-order neurons expressing the
orexigenic peptide melanin-concentrating hormone
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(MCH) in the lateral hypothalamic area (LHA). In
support of this model, both the PVN and LHA are
supplied by melanocortin-containing projections from
the Arc (8, 9) and express MC-4 receptor mRNA (7a,
28). In addition, expression of CRH and MCH is altered
by changes in energy balance (5, 32). We hypothesized,
therefore, that CRH and MCH neurons are targets of
a-MSH signaling, whereas POMC and AgRP gene ex-
pression appear to be regulated by a direct action of
leptin, binding to leptin receptors located on Arc neu-
rons transcribing these peptides (1, 7, 10). Thus we
also hypothesized that intracerebroventricular a-MSH
infusion would alter CRH and MCH gene expression
via melanocortin receptors located in areas of the brain
containing these neuropeptides, but would not alter
POMC or AgRP expression.
To test these hypotheses, we administered a-MSH
into the third ventricle of rats over 6 days to ascertain
its chronic effects on food intake, body weight, plasma
hormone levels, body composition, and neuropeptide
expression in the hypothalamus. In addition, we hy-
pothesized that a single injection of a-MSH would
acutely activate neuronal substrates in energy regula-
tion pathways. To identify these sites, we injected rats
in the third ventricle with a-MSH and quantified c-
Fos-like immunoreactive nuclei in the forebrain and
hindbrain.
MATERIALS AND METHODS
Animals
All studies used male Long-Evans rats (300–350 g) from
the breeding colony maintained by the Department of Psy-
chology at the University of Washington housed individually
in wire-mesh hanging cages (experiments 1 and 3) or male
Wistar rats weighing 300–350 g (Simonsen Laboratories,
Gilroy, CA) were housed in polycarbonate cages (experiment
2) in a temperature-controlled vivarium on a 12:12-h light-
dark schedule. Unless otherwise specified, animals were
given free access to pelleted rat chow (Harlan-Teklad, Mad-
ison, WI, experiments 1 and 3; Ralston Purina, St. Louis, MO,
experiment 2) and water at all times. All procedures were
performed according to institutional guidelines of the Animal
Care and Use Committee at the Seattle Veterans Affairs
Medical Center and University of Washington.
Cannula Placement
Rats were habituated with daily handling for 1 wk before
surgery. After anesthesia induced by intraperitoneal injec-
tion of ketamine-xylazine (60 mg/kg ketamine and 8 mg/kg
xylazine), a 21-gauge cannula (Plastics One, Roanoke, VA)
was placed stereotaxically into the third ventricle using a
previously described method (37, 39). Cannula placement
was verified 1 wk after surgery by intracerebroventricular
injection of 10 ng angiotensin II (American Peptide, Sunny-
vale, CA) diluted in 1 ml saline. Animals not consuming at
least 5 ml water 30 min postinjection were excluded as
cannulation failures (4% of all rats). Experiments were per-
formed at least 2–3 wk after surgery.
Experimental Protocols
Experiment 1: acute effect of a-MSH on food intake. Can-
nulas were surgically implanted in the third ventricle of
Long-Evans rats, as described above. Food hoppers were
removed from the animal cages at 1500 and weighed. At
1600, animals were injected in the third ventricle with either
5 ml of sterile, 0.9% preservative-free saline (Fujisawa USA,
Deerfield, IL) or an equal volume of human a-MSH (Penin-
sula Laboratories, Belmont, CA) in saline using an injector
(Plastics One) attached by polyethylene tubing to a 25-ml
glass syringe (Hamilton, Reno, NV). A study comparing doses
of 0, 2.5, 25, and 50 mg a-MSH (n 5 5–7/group) was per-
formed. For each trial, infusate was delivered manually over
a period of 2 min, after which time animals received an
intramuscular injection of 8 mg gentamicin sulfate to prevent
infection and were immediately returned to their home
cages. Food hoppers were replaced on the cages at 1730, and
lights out occurred at 1800. Food-intake data were collected
at the 1-, 2-, 3-, 4-, 16-, and 24-h time points. A recovery
period of at least 6 days was allowed between trials.
Experiment 2: chronic intracerebroventricular a-MSH in-
fusion. On the basis of preliminary results showing that a
single intracerebroventricular injection of 10 mg a-MSH re-
duces 4-h food intake in Wistar rats and that a chronic
intracerebroventricular infusion of 96 mg/day is no more
effective than 24 mg/day at reducing food intake and body
weight after 6 days (data not shown), we selected a dose of 24
mg/day for this study. Three weeks after cannula placement,
each rat was anesthetized by intraperitoneal injection of
ketamine-xylazine and received a subcutaneous osmotic
minipump (Azlet model 2001, Palo Alto, CA) delivering either
1 mg/ml human a-MSH in 0.9% saline vehicle at a rate of 1
ml/h (24 mg/day; n 5 9) or vehicle alone (n 5 7) via a
polyethylene catheter that was connected to the ventricular
cannula. A saline-infused group pair-fed to the food intake of
the a-MSH group (n 5 9) was also included to determine if
some responses to intracerebroventricular a-MSH were sec-
ondary to reduced food intake. The amount of chow provided
to each pair-fed animal on each treatment day was equal to
the measured amount of chow consumed by its a-MSH-
treated partner during the previous 24-h period. Animals
received continuous intracerebroventricular infusions of ei-
ther a-MSH or saline for 6 days and were lightly anesthe-
tized by brief exposure to carbon dioxide before decapitation
between 1100 and 1300 on the 6th day of infusion. Trunk
blood, carcasses, and brains were collected upon decapita-
tion. Blood was centrifuged, and plasma was stored at 220°C
and brains were stored at 280°C. Carcasses were stored at
220°C.
Experiment 3: acute effect of a-MSH on c-Fos-like immu-
noreactivity in the brain. Three weeks after cannula place-
ment in the third ventricle, male Long-Evans rats were
assigned to one of two weight-matched groups and injected in
the third ventricle with either 5 ml of saline (n 5 5) or 20 mg
a-MSH in saline (n 5 10). Injections were performed between
1000 and 2000, after which the animals were immediately
returned to their home cages and their food hoppers were
removed. After 110 min, rats were anesthetized with pento-
barbital sodium (60 mg ip) and transcardially perfused with
isotonic saline of neutral pH followed by a 4% paraformalde-
hyde solution. Brains were removed immediately and post-
fixed in paraformaldehyde for 1 wk before assay for c-Fos-like
immunoreactivity (cFLI).
Assays and Data Analyses
Plasma assays. Radioimmunoassays were used to measure
plasma levels of corticosterone and immunoreactive insulin
as previously described (13, 37). Plasma glucose was deter-
mined by the glucose oxidase method (Beckman Instruments,
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Brea, CA). Plasma leptin levels were determined by radioim-
munoassay using a rat-specific antibody (Linco, St. Louis,
MO) (21).
Analysis of body composition. Postmortem body fat and
nonfat mass were measured by dual-energy X-ray absorpti-
ometry (DEXA; QDR 1500, Hologic, Waltham, MA) using
software designed for rats. The DEXA scanner was calibrated
to quantify nonfat mass as lean tissue comprised of 60%
water, excluding bone mass. A tissue calibration scan was
performed every 4 h to correct for DEXA performance vari-
ables over the course of the analysis. Intra-assay coefficient
of variation for fat mass was 6.3%. Validation of DEXA for
analysis of body fat stores in rats has been documented
previously (3, 24, 44).
In situ hybridization to AgRP, POMC, CRH, and MCH
mRNA. Brains from experiment 2 were immediately frozen
on crushed dry ice and subsequently sectioned coronally at 14
mm in a cryostat and mounted on RNAse-free slides. Ribo-
probes complementary to rat POMC (a generous gift of
Dr. Robert Steiner), MCH, and AgRP mRNAs (constructs
provided by Dr. Tina M. Hahn) were used for hybridization
after labeling with 33P, as previously described (36). Hybrid-
ization for CRH mRNA was performed using a 33P-labeled
antisense oligonucleotide probe based on cDNA sequences of
rat CRH genes, as described elsewhere (39). Slides for in situ
hybridization (ISH) to POMC mRNA were selected from the
region of the Arc rostral to the ventromedial hypothalamic
nucleus (VMN), and sections for MCH and AgRP were taken
from the midregion of the Arc, at the level of the VMN. Slides
for CRH mRNA were selected from the PVN. All slides were
selected by an investigator blinded to the treatment group.
Labeled slides were washed under high-stringency condi-
tions and opposed to X-ray film to generate autoradiographs,
which were analyzed by computer densitometry. With the
use of a standard curve, autoradiographic optical density and
hybridization area were determined on six to eight sections
per rat using the MCID computer densitometry system (Im-
aging Research, St. Catherine’s, Ontario, Canada). The prod-
uct of hybridization area (pixels) and density (mCi/pixel) was
used as an index of overall neuropeptide mRNA levels, which
are expressed as percentage of mean control values (34–36, 39).
cFLI. Each postfixed brain was rinsed two to three times in
PBS and sectioned at 50 mm on a Vibratome in a PBS bath.
Coronal sections taken from the forebrain and horizontal
slices from the hindbrain were processed for cFLI as de-
scribed in detail elsewhere (40). Sections were mounted on
slides, and the number of cFLI-positive cell nuclei was quan-
tified in specific brain areas using the MCID computer grain
counting system (Imaging Research).
Statistical Analyses
All statistical analyses were carried out using Prism 2.01
(GraphPad Software, San Diego, CA) statistical software.
Data are presented as group mean values (6SE). For exper-
iments with greater than two study groups, comparisons
were performed with one-way ANOVA and Newman-Keuls
post hoc test. A Student’s t-test was used for two-group
comparisons. A P value #0.05 between group mean values
was considered statistically significant.
RESULTS
Experiment 1: Acute Effect of Intracerebroventricular
a-MSH Infusion on Food Intake
As compared with intracerebroventricular vehicle,
intracerebroventricular administration of 2.5 mg of
a-MSH 2 h before the dark cycle caused a nonsignifi-
cant 27.5% decrease of cumulative 4-h food intake in
nonfasted rats (Fig. 1). Food intake was significantly
suppressed by 42.1% (7.9 6 0.5 vs. 4.6 6 0.8 g, P ,
0.05) after 25 mg intracerebroventricular a-MSH, and
no additional food intake suppression was detected at
the 50-mg dose. Twenty-four hours after a-MSH infu-
sion, cumulative food intake and body weight across all
dose groups did not differ significantly from vehicle-
treated control values.
Experiment 2: Chronic Intracerebroventricular
a-MSH Infusion
Food intake. Cumulative food intake over 6 days was
reduced by 10.7% (119.3 6 5.0 vs. 106.5 6 3.9 g, P ,
0.05) in rats receiving 24 mg/day a-MSH as a continu-
ous intracerebroventricular infusion compared with
saline-treated controls fed ad libitum (Table 1). Anal-
ysis of the time course of this effect demonstrated a
39.9% inhibition of food intake that occurred during
the first 24 h (12.7 6 2.3 vs. 7.6 6 0.9 g, P , 0.05), with
food intake returning to near normal levels on subse-
quent days. After an initial suppression of energy in-
take, therefore, the anorectic effect of a-MSH was no
longer detected. By design, the intake of the saline-
treated, pair-fed group was matched to that of the
a-MSH group and was also significantly below that of
controls fed ad libitum.
Body weight and composition. As summarized in
Table 2, mean body weight at baseline was similar
among the three groups of rats. When expressed as a
percentage of initial body weight, weight at the time of
death was decreased by 3.9 6 0.8% in a-MSH-treated
rats and 3.1 6 0.9% in the saline-infused pair-fed
animals (P , 0.01 for both comparisons) and remained
unchanged in the saline-infused control group. When
expressed as a percentage of final body weight of the
saline control group, weight was decreased by 4.3% in
the a-MSH group and 3.6% in the pair-fed group. Final
body weight was not significantly different between the
saline-infused pair-fed and the a-MSH-infused groups.
Relative to ad libitum-fed controls, total body fat
mass determined by DEXA analysis was 2.2 g less in
Fig. 1. Effect of acutely administered intracerebroventricular a-me-
lanocyte-stimulating hormone (a-MSH) on 4-h food intake at 0-, 2.5-,
5-, 25-, and 50-mg doses. *P , 0.05 vs. saline (n 5 5–7 animals/
group).
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a-MSH-infused animals and 0.9 g less in the pair-fed
group [P 5 not significant (NS) between all groups],
whereas lean mass was reduced by 15.7 and 13.7 g in
the a-MSH and pair-fed groups, respectively (P 5 NS
between all groups, Table 2). Total weight loss was,
therefore, comprised of decreases in both fat and lean
mass, and percent body fat was not significantly differ-
ent in either the a-MSH-infused or pair-fed groups
compared with the ad libitum-fed controls (20.3% in
the a-MSH-infused group and 10.3% in the pair-fed
group).
Plasma values. Nonfasting plasma insulin levels
were reduced by 29.3% in the a-MSH group vs. saline-
treated rats fed ad libitum (207.3 6 25.7 vs. 293.1 6
23.9 pmol/l, P , 0.05) and by 38.5% in the pair-fed
group vs. saline (180.3 6 11.1 pmol/l, P , 0.01 vs.
saline-infused rats fed ad libitum), but the a-MSH and
pair-fed groups were not significantly different (Fig.
2A). Plasma glucose levels were not significantly dif-
ferent among groups (Fig. 2A). Plasma leptin was de-
creased nonsignificantly by 20.1% in the a-MSH group
compared with the saline group (1.2 6 0.1 vs. 1.5 6 0.2
ng/ml) and was decreased by 34.4% in the saline pair-
fed group compared with controls fed ad libitum (1.0 6
0.1 ng/ml, P , 0.05)(Fig. 2B). Plasma corticosterone
levels were increased by 51.0% in the a-MSH-infused
group compared with the saline-infused group (94.1 6
33.13 vs. 62.3 6 15.5 ng/ml) and by 7.2% in the saline
pair-fed group (66.8 6 14.22 ng/ml) (Fig. 2B), although
neither difference reached statistical significance.
ISH. As expected, hybridization to both POMC and
AgRP mRNA in the hypothalamus was detected only in
the Arc. POMC mRNA levels in the rostral Arc were
nonsignificantly suppressed by 13.1 6 4.0 and 16.1 6
9.7% in the a-MSH and pair-fed groups relative to
saline controls fed ad libitum (Fig. 3). By comparison,
AgRP mRNA levels in the Arc were elevated by 30.4 6
10.1 and 12.6 6 8.6% in the a-MSH and pair-fed
groups, respectively, compared with ad libitum-fed
controls, although neither difference reached statisti-
cal significance. CRH mRNA levels in the PVN were
decreased by 18.2 6 10.4% and increased by 24.2 6
38.9% in the a-MSH and pair-fed groups, respectively,
compared with saline controls (P 5 NS for both com-
parisons). MCH mRNA levels in the LHA were in-
creased by 121.1 6 51.3 and 111.3 6 41.0% in the
a-MSH and pair-fed groups compared with saline con-
trols (P 5 NS for both comparisons).
Experiment 3: Acute Effect of a-MSH on cFLI
in the Brain
In the brain stem, the number of nuclei that stained
positively for cFLI in the lateral parabrachial nucleus
(lPBN) was increased by 627% of intracerebroventricu-
larly saline-injected control levels 2 h after intracere-
Table 1. Daily and cumulative food intake
Food Intake, g
Saline a-MSH Pair-fed
Day 1 12.662.3 7.660.9* 5.161.1†
Day 2 19.960.9 17.661.1 16.661.1
Day 3 18.760.7 18.061.2 17.561.1
Day 4 22.860.9 20.760.9 20.760.9
Day 5 23.161.1 22.061.0 21.660.8
Day 6 22.061.1 20.660.7 20.660.7
Cumulative 119.365.0 106.563.9* 102.063.7*
Values are means 6 SE. Effect of chronic a-melanocyte-stimulat-
ing hormone (a-MSH) infusion on daily and cumulative food intake,
saline vs. a-MSH and saline pair-fed, *P , 0.05 vs. saline controls,
†P , 0.01 vs. saline controls by 1-way ANOVA.
Table 2. Body weight and body composition
Saline a-MSH Pair-Fed
Initial body wt, g 365.965.8 362.167.6 361.967.8
Body wt at death, g 367.467.2 347.867.9* 350.569.4*
Fat at death, g 25.361.4 23.161.0 24.461.5
Lean body mass at
death, g 313.568.1 297.867.0 299.868.1
%Body fat at death 6.960.5 6.660.2 7.260.3
Values are means 6 SE. Baseline and body weight at death and
body composition at death after chronic infusion as determined by
dual-energy X-ray absorptiometry analysis, saline vs. a-MSH and
saline pair-fed. *P , 0.05 vs. saline.
Fig. 2. Mean 6 SE plasma values after 6-day infusion of a-MSH. A:
plasma insulin levels, *P , 0.05 vs. saline controls, **P , 0.01 vs.
saline controls; plasma glucose levels, P 5 not significant (NS). B:
plasma leptin levels, *P , 0.05 vs. saline controls; plasma cortico-
sterone levels, P 5 NS. The saline group is represented by open bars
(n 5 7), the a-MSH group by solid bars (n 5 9), and the saline
pair-fed group by hatched bars (n 5 9).
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broventricular injection of a-MSH at a dose of 20 mg
(7.4 6 1.9 vs. 53.8 6 7.0 cFLI-positive nuclei, P ,
0.001) and was nonsignificantly increased by 185% in
the NTS. In the forebrain, a-MSH also increased fos
staining in the supraoptic nucleus (SON), the PVN, the
central nucleus of the amygdala (CeA), and in the Arc.
The number of nuclei with cFLI in the SON was in-
creased with intracerebroventricular a-MSH by
1,142% (7.2 6 1.9 vs. 89.4 6 17.0 cFLI-positive nuclei,
P , 0.01), in the PVN by 254% (67.3 6 32.2 vs. 238.0 6
27.9 cFLI-positive nuclei, P , 0.01), and in the CeA by
204% (19.0 6 7.6 vs. 57.7 6 10.4 cFLI-positive nuclei,
P , 0.05). The number of cFLI-positive nuclei in the
Arc was nonsignificantly increased by 46% (Fig. 4).
DISCUSSION
Summary of Findings
The melanocortin system is proposed to be an impor-
tant hypothalamic pathway involved in energy ho-
meostasis (25, 38). To compare the response to acute
and chronic central melanocortin receptor stimulation
and to investigate the effect of increased central ner-
vous system (CNS) melanocortin signaling on hypotha-
lamic and brain stem areas associated with energy
homeostasis, we infused a-MSH into the third cerebral
ventricle of adult male rats. We found that a single
intracerebroventricular injection of a-MSH, at a dose
that reduces 4-h intake, activated neurons (as indi-
cated by increased cFLI in cell nuclei) in several fore-
brain areas, as well as in the lPBN, an important
metabolic relay area of the brain stem. A reduction in
body weight, however, was not observed after a single
intracerebroventricular a-MSH injection. In contrast,
continuous intracerebroventricular administration of
a-MSH for 6 days did result in sustained decreases of
both food intake and body weight, although the ano-
rectic response to chronic infusion of a-MSH was great-
est during the first 24 h of infusion and was not signif-
icant thereafter. Moreover, a chronic infusion of
a-MSH did not selectively reduce body fat and failed to
alter expression of specific hypothalamic neuropeptide
mRNAs. Therefore, although a-MSH acts in the CNS
to induce a state of negative energy balance, its efficacy
wanes with chronic administration, suggesting that a
competing mechanism attenuates its effectiveness.
Acute Injection of a-MSH
To investigate the acute effects of intracerebroven-
tricular a-MSH on food intake, we measured food con-
sumption in response to different doses of a-MSH ad-
ministered to conscious, nonfasted rats 2 h before the
beginning of the nocturnal cycle. We found that, al-
though a 25-mg injection of a-MSH reduced food intake
by 42.1% over 4 h compared with saline-injected con-
trols (P , 0.05, experiment 1), a compensatory increase
of food intake occurred subsequently, such that neither
24-h food intake nor body weight was significantly
affected. Higher doses were no more effective in their
ability to suppress food intake or to induce weight loss.
This finding differs from the effects of the synthetic
melanocortin receptor agonist MTII, which, at a dose
of 1 nmol icv, elicits a more sustained anorexia
and a significant weight loss after 24 h (40) despite an
initial response (at 4 h) comparable to that of 25 mg
(15 nmol) of a-MSH. A 10-mg icv (6 nmol) dose of
Nle4DPhe7alpha (NDP-MSH), an a-MSH analog, also
maintains a significant 34% suppression of food intake
over a 24-h period compared with vehicle control (6).
Because MTII and NDP-MSH are engineered to bind
the MC-4 receptor with higher affinity and, as syn-
thetic compounds, may be cleared less readily than
a-MSH (17), the prolonged effects of MTII and NDP-
MSH on food intake could reflect a sustained increase
of neuronal melanocortin signaling. It is therefore pos-
sible that the short duration of a-MSH-induced an-
Fig. 4. Mean 6 SE c-Fos-like immunoreactivity (cFLI)-positive nu-
clei of the brain 2 h after intracerebroventricular administration of
20 mg a-MSH (n 5 10) or saline (n 5 5). Parabrachial nucleus (PBN),
***P , 0.001 vs. saline; nucleus of the solitary tract (NTS), P 5 NS;
PVN, **P , 0.01 vs. saline; Arc, P 5 NS; supraoptic nucleus (SON),
**P , 0.01 vs. saline; central nucleus of the amygdala (CeA), *P ,
0.05 vs. saline (n 5 4–10 animals/group).
Fig. 3. Effect of chronic a-MSH infusion on hypothalamic neuropep-
tide expression determined by in situ hybridization. Values are
means 6 SE. Levels of proopiomelanocortin (POMC) mRNA in the
region of the arcuate nucleus rostral to the ventromedial hypotha-
lamic nucleus (VMN); levels of agouti-related peptide (AgRP) mRNA
in the midregion of the arcuate nucleus (Arc) at the level of the VMN;
levels of corticotropin-releasing hormone (CRH) mRNA in the para-
ventricular nucleus (PVN); levels of melanin-concentrating hormone
(MCH) mRNA in the midregion of the lateral hypothalamic area
(LHA), at the level of the VMN. The a-MSH group is represented by
solid bars (n 5 8), the saline group by open bars (n 5 4 for MCH
mRNA, n 5 5 for all others), and the saline pair-fed group by hatched
bars (n 5 8).
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orexia compared with MTII and NDP-MSH is due
simply to a relatively short-lived stimulation of central
melanocortin receptors, in which case, a chronic intra-
cerebroventricular infusion of a-MSH should elicit a
more durable anorexic response. To investigate this
hypothesis, we measured the effect of continuous in-
tracerebroventricular administration of a-MSH for 6
days.
Chronic Infusion of a-MSH
Although both vehicle- and a-MSH-treated animals
experienced reduced food intake and body weight on
the first day of infusion (presumably related to
minipump implantation), animals infused with a-MSH
consumed 39.9% less food than saline-infused, ad libi-
tum-fed controls. Thus, whereas an acute intracerebro-
ventricular injection of 25 mg a-MSH suppressed food
intake at 4 h, but not at 24 h, continuous infusion of a
comparable dose (24 mg) induced a cumulative reduc-
tion of food intake that was sustained for at least 24 h
with no compensatory increase of food intake over the
subsequent 6 days of a-MSH infusion. This demonstra-
tion that the duration of a-MSH-induced anorexia is
increased by chronic intracerebroventricular infusion
supports the hypothesis that sustained melanocortin
signaling is necessary to achieve the more durable
anorexia induced by MTII or NDP-MSH. By day 2,
however, food intake differed by only 11.6% between
these two groups and was only 5.9% lower for the
remainder of the study. This attenuation of a-MSH-
induced anorexia during continuous infusion is consis-
tent with the development of either melanocortin
receptor downregulation, compensatory responses in-
volving other neuronal pathways, or both.
By day 6, the a-MSH-infused group weighed 4.3%
less than the saline-infused controls, whereas saline-
infused animals pair-fed to the a-MSH group exhibited
a 3.6% weight loss that was not significantly different
from that seen in the a-MSH-infused group. Although
these findings suggest that decreased food intake in-
duced by chronic infusion of a-MSH is sufficient to
explain the measured weight reduction, they do not
exclude an effect of a-MSH on energy expenditure.
Postmortem body composition analysis indicated that
the percentages of lean and fat mass were similar
between the a-MSH and the two control groups and
that lost weight was comprised of both lean and fat
tissue. Thus weight loss induced by chronic central
administration of a-MSH is modest and is not com-
prised preferentially of adipose tissue, as has been
reported for leptin.
As expected, reduced body weight in both the a-MSH
and pair-fed groups was associated with comparable
reductions of plasma insulin and leptin levels relative
to ad libitum-fed controls. This finding suggests that
suppression of basal levels of these plasma hormones
was the consequence of reduced food intake and weight
loss rather than an independent effect of a-MSH on
hormone secretion. However, our study did not inves-
tigate insulin secretory responses or systemic insulin
action. Thus further experiments are necessary to clar-
ify this issue. Measurements of plasma corticosterone
and glucose levels also failed to demonstrate indepen-
dent effects of a-MSH on these measures. Taken to-
gether, these findings suggest that in normal rats,
chronic intracerebroventricular infusion of a-MSH
does not substantially influence basal plasma levels of
hormones involved in energy homeostasis or glucose
homeostasis independent of its effect to reduce food
intake and body weight.
Significant changes in hypothalamic neuropeptide
mRNA levels were not observed after chronic a-MSH
infusion. Although they did not reach statistical signif-
icance, the direction and magnitude of changes of
POMC, CRH, MCH, and AgRP mRNA we detected are
consistent with the response predicted for the modest
decrease of body weight and leptin and insulin levels
experienced by the a-MSH and pair-fed groups.
Brain cFLI After a-MSH Injection
Although not all CNS neurons express c-Fos on ac-
tivation, detection of those that do provides a useful
means of identifying CNS targets of specific pharma-
cological stimuli. We found that 2 h after 20 mg of
a-MSH was administered into the third cerebral ven-
tricle, marked increases in cFLI-positive nuclei were
seen in the PVN, CeA, and the lPBN, as previously
demonstrated with MTII (40) and NDP-MSH (6; Fig.
5). c-Fos immunostaining of the lPBN by a-MSH may
have arisen from activation of melanocortin-sensitive
hypothalamic projections to the brain stem or by direct
activation of melanocortin receptors located in the
lPBN by a-MSH carried from the third to the fourth
ventricle. Because MTII delivered into either the lat-
eral or fourth ventricle is equally potent in suppressing
food intake and body weight (14), it is possible that
a-MSH exerts direct effects in brain stem feeding areas
that may explain c-Fos induction in the lPBN.
The parvocellular PVN, CeA, and lPBN are compo-
nents of a pathway that integrates centers regulating
food intake and body weight with satiety centers in the
brain stem. The activation of all three areas by a-MSH
suggests that it may enhance in the perception of
satiety and thereby facilitate the consumption of
smaller meals, which, over time, results in a modest
decrease in body weight. However, meal size was not
measured in our study, and intracerebroventricularly
administered a-MSH also increases mean arterial
blood pressure via an action that may involve the same
brain nuclei (8). Further studies are therefore war-
ranted to differentiate activation by a-MSH of cardio-
vascular versus energy balance circuits along this
pathway.
Perspectives
Previous studies have shown that leptin stimulates
POMC expression in the Arc (7, 36), suggesting that
melanocortin signaling may be downstream of leptin in
a pathway leading to anorexia. Support for this hy-
pothesis was provided by the observation that the
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anorectic properties of leptin can be blocked by pre-
treatment with the melanocortin receptor antagonist
SHU-9119 (38) and that mice deficient in MC-4 recep-
tor signaling have an attenuated response to leptin
(25). Because the leptin receptor is expressed by Arc
POMC neurons (7), these findings suggest that at least
some of leptin’s effects on energy homeostasis are me-
diated by increased a-MSH signaling via the MC-4
receptor.
Our current findings, however, suggest that CNS
leptin signaling must involve pathways additional to
melanocortin signaling, in agreement with a previous
study (4). For example, leptin’s ability to induce adi-
pose-specific weight loss was not induced by chronic
intracerebroventricular a-MSH, and the magnitude of
a-MSH-induced anorexia and weight loss with chronic
central administration is less than that seen with lep-
tin. In addition, CNS melanocortin signaling must in-
volve pathways not activated by leptin, because a
pronounced increase of cFLI-positive nuclei was seen
in the lPBN in response to intracerebroventricular
a-MSH, whereas intracerebroventricular leptin does
not have this effect (40).
These data support a model (Fig. 6) in which a-MSH
induces reductions in food intake via activation of
MC-4 receptors in both the brain stem and hypothala-
mus. On the basis of previous studies, an increase of
leptin delivery to the brain increases forebrain MC-4-
receptor signaling via both an increase in POMC ex-
pression and a decrease in AgRP expression in Arc
neurons. Increased MC-4 signaling in second-order
neurons involved in food intake regulation may then
promote anorexia. For example, activation of CRH- or
suppression of MCH-containing neurons may contrib-
ute to the response to MC-4-receptor stimulation, al-
though we were unable to demonstrate significant ef-
fects of a-MSH on either CRH or MCH mRNA levels.
Thus other neurons, such as thyrotropin-releasing hor-
mone neurons of the PVN, may also contribute to the
anorectic effects of a-MSH (12).
Leptin is hypothesized to affect food intake not only
by stimulating catabolic effector pathways such as the
Fig. 5. a-MSH dramatically increases number of c-Fos-
positive nuclei in the PVN and lateral PBN (A, C) com-
pared with saline controls (B, D).
Fig. 6. Proposed model for the role of melanocortins
in leptin signaling. Leptin regulates hypothalamic
gene expression via leptin receptors located on
POMC and AgRP neurons. Leptin indirectly regu-
lates food intake by upregulating POMC expression
and increasing a-MSH levels in the PVN, thereby
activating melanocortin signaling in CRH and MCH
neurons of the hypothalamus. Hypothalamic projec-
tions from the PVN and LHA transduce energy bal-
ance information to the NTS and subsequently to
autonomic preganglionic neurons. DMX, dorsal mo-
tor nucleus of the vagal nerve.
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melanocortin system, but also by inhibiting anabolic
signaling systems such as NPY/AgRP neurons in the
Arc. As weight loss induced by chronic intracerebro-
ventricular a-MSH proceeds, therefore, the decline in
adiposity signaling (in the form of circulating insulin
and leptin) to the CNS is proposed to activate NPY/
AgRP neurons and thereby offset the anorectic action
of a-MSH. This scenario is consistent with current
literature and provides a viable explanation for our
results. If correct, the clinical efficacy of melanocortin
agonists in the treatment of obesity may be limited by
the effect of weight loss to activate compensatory re-
sponses that antagonize the effect of melanocortins.
This possibility suggests that the efficacy of such com-
pounds will be increased if used in combination with
drugs that block such compensatory responses, and
further studies are warranted to test this hypothesis.
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